vs

Side-by-side financial comparison of LATTICE SEMICONDUCTOR CORP (LSCC) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $145.8M, roughly 1.0× LATTICE SEMICONDUCTOR CORP). LATTICE SEMICONDUCTOR CORP runs the higher net margin — -5.2% vs -5.5%, a 0.3% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 9.3%). LATTICE SEMICONDUCTOR CORP produced more free cash flow last quarter ($44.0M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 8.4%).

Lattice Semiconductor Corporation is an American semiconductor company specializing in the design and manufacturing of low power field-programmable gate arrays (FPGAs). Headquartered in the Silicon Forest area of Hillsboro, Oregon, the company also has operations in San Jose, Calif., Shanghai, Manila, Penang, and Singapore. Lattice Semiconductor has more than 1000 employees and an annual revenue of more than $660 million as of 2022. The company was founded in 1983 and went public in 1989. It ...

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

LSCC vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.0× larger
TARS
$151.7M
$145.8M
LSCC
Growing faster (revenue YoY)
TARS
TARS
+119.1% gap
TARS
128.4%
9.3%
LSCC
Higher net margin
LSCC
LSCC
0.3% more per $
LSCC
-5.2%
-5.5%
TARS
More free cash flow
LSCC
LSCC
$31.0M more FCF
LSCC
$44.0M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
8.4%
LSCC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LSCC
LSCC
TARS
TARS
Revenue
$145.8M
$151.7M
Net Profit
$-7.6M
$-8.4M
Gross Margin
68.5%
Operating Margin
30.7%
-5.3%
Net Margin
-5.2%
-5.5%
Revenue YoY
9.3%
128.4%
Net Profit YoY
14.6%
63.8%
EPS (diluted)
$-0.06
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LSCC
LSCC
TARS
TARS
Q1 26
$145.8M
Q4 25
$151.7M
Q3 25
$133.3M
$118.7M
Q2 25
$124.0M
$102.7M
Q1 25
$120.2M
$78.3M
Q4 24
$117.4M
$66.4M
Q3 24
$127.1M
$48.1M
Q2 24
$124.1M
$40.8M
Net Profit
LSCC
LSCC
TARS
TARS
Q1 26
$-7.6M
Q4 25
$-8.4M
Q3 25
$2.8M
$-12.6M
Q2 25
$2.9M
$-20.3M
Q1 25
$5.0M
$-25.1M
Q4 24
$16.5M
$-23.1M
Q3 24
$7.2M
$-23.4M
Q2 24
$22.6M
$-33.3M
Gross Margin
LSCC
LSCC
TARS
TARS
Q1 26
68.5%
Q4 25
Q3 25
67.9%
Q2 25
68.4%
Q1 25
68.0%
Q4 24
61.1%
Q3 24
69.0%
Q2 24
68.3%
Operating Margin
LSCC
LSCC
TARS
TARS
Q1 26
0.7%
Q4 25
-5.3%
Q3 25
-1.2%
-12.2%
Q2 25
3.8%
-21.6%
Q1 25
5.8%
-33.5%
Q4 24
-10.4%
-36.8%
Q3 24
5.9%
-52.3%
Q2 24
18.2%
-81.6%
Net Margin
LSCC
LSCC
TARS
TARS
Q1 26
-5.2%
Q4 25
-5.5%
Q3 25
2.1%
-10.6%
Q2 25
2.3%
-19.8%
Q1 25
4.2%
-32.1%
Q4 24
14.1%
-34.8%
Q3 24
5.7%
-48.7%
Q2 24
18.2%
-81.6%
EPS (diluted)
LSCC
LSCC
TARS
TARS
Q1 26
$-0.06
Q4 25
$-0.17
Q3 25
$0.02
$-0.30
Q2 25
$0.02
$-0.48
Q1 25
$0.04
$-0.64
Q4 24
$0.12
$-0.57
Q3 24
$0.05
$-0.61
Q2 24
$0.16
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LSCC
LSCC
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$133.9M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$714.1M
$343.4M
Total Assets
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LSCC
LSCC
TARS
TARS
Q1 26
$133.9M
Q4 25
$417.3M
Q3 25
$117.9M
$401.8M
Q2 25
$107.2M
$381.1M
Q1 25
$127.6M
$407.9M
Q4 24
$136.3M
$291.4M
Q3 24
$124.3M
$317.0M
Q2 24
$109.2M
$323.6M
Total Debt
LSCC
LSCC
TARS
TARS
Q1 26
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
LSCC
LSCC
TARS
TARS
Q1 26
$714.1M
Q4 25
$343.4M
Q3 25
$706.4M
$335.1M
Q2 25
$687.0M
$332.6M
Q1 25
$707.9M
$342.5M
Q4 24
$710.9M
$224.5M
Q3 24
$703.5M
$237.5M
Q2 24
$698.8M
$252.2M
Total Assets
LSCC
LSCC
TARS
TARS
Q1 26
$883.1M
Q4 25
$562.2M
Q3 25
$844.4M
$534.6M
Q2 25
$808.6M
$495.0M
Q1 25
$823.6M
$500.8M
Q4 24
$843.9M
$377.0M
Q3 24
$853.7M
$376.3M
Q2 24
$827.5M
$376.8M
Debt / Equity
LSCC
LSCC
TARS
TARS
Q1 26
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LSCC
LSCC
TARS
TARS
Operating Cash FlowLast quarter
$57.6M
$19.3M
Free Cash FlowOCF − Capex
$44.0M
$13.0M
FCF MarginFCF / Revenue
30.2%
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$153.3M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LSCC
LSCC
TARS
TARS
Q1 26
$57.6M
Q4 25
$19.3M
Q3 25
$47.1M
$18.3M
Q2 25
$38.5M
$-29.4M
Q1 25
$31.9M
$-20.7M
Q4 24
$45.4M
$-22.2M
Q3 24
$44.0M
$-8.7M
Q2 24
$21.9M
$-14.4M
Free Cash Flow
LSCC
LSCC
TARS
TARS
Q1 26
$44.0M
Q4 25
$13.0M
Q3 25
$34.0M
$16.3M
Q2 25
$31.3M
$-30.4M
Q1 25
$23.3M
$-21.2M
Q4 24
$39.7M
$-22.3M
Q3 24
$39.4M
$-8.9M
Q2 24
$14.8M
$-15.4M
FCF Margin
LSCC
LSCC
TARS
TARS
Q1 26
30.2%
Q4 25
8.6%
Q3 25
25.5%
13.8%
Q2 25
25.2%
-29.6%
Q1 25
19.4%
-27.1%
Q4 24
33.8%
-33.5%
Q3 24
31.0%
-18.6%
Q2 24
11.9%
-37.8%
Capex Intensity
LSCC
LSCC
TARS
TARS
Q1 26
9.3%
Q4 25
4.2%
Q3 25
9.8%
1.6%
Q2 25
5.8%
1.0%
Q1 25
7.2%
0.8%
Q4 24
4.9%
0.1%
Q3 24
3.7%
0.6%
Q2 24
5.8%
2.5%
Cash Conversion
LSCC
LSCC
TARS
TARS
Q1 26
Q4 25
Q3 25
16.86×
Q2 25
13.23×
Q1 25
6.35×
Q4 24
2.75×
Q3 24
6.12×
Q2 24
0.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons